서울대학교 CCADD 연구실

ABOUT
PRINCIPAL
INVESTIGATOR
- HOWARD LEE
- TEACHING
- BLOG
PEOPLE
- MEMBERS
- ALUMNI
- PICTURES
RESEARCH
PUBLICATIONS
NEWS
KOREAN

RESEARCH

OVERVIEW
PROJECT LIST
CURRENT RESEARCH
PREVIOUS RESEARCH

SEARCH

[NEWS]

Check out this CCADD intro video clip @YouTube!

Check out the YouTube video, which is pretty funny but tells who we are in only 30 seconds. Hyewon and other lab members did a fantastic job! Kudos and congratulations!

[NEWS]

The story behind the name and logo of CCADD

The name CCADD was the culmination of several chalk talks and an overnight workshop among the initial team members (Howard, Yoomin, Siun, and Hyun A). We were very much interested in creating a new center, which focuses on generating innovative convergence knowledge to revolutionize the clinical drug development paradigm. After a series of conversations, discussions, and heated debates sometimes, the name Convergence for Alternative Drug Development Sciences (CADDS) was proposed. However, we soon realized that ‘alternative drug development’ could be misleading since alternative drugs were not what we intended to concentrate on. So, CADDS was discarded.

After several more conversations, the name Center for Convergence Approaches in Drug Development (CCADD) finally came up. Everyone liked this name because it sounded cool (pronounced “See-Cad”), was easy to memorize, and contained the first letters of what we later dubbed ‘core values’ for us, i.e., challenge, creativity, accountability, diversity, and difference. Voila!

The next thing we had to do was to design a logo that could visually capture the essence of CCADD and its people. It soon turned out that, however, it was not something that we could do by ourselves. Instead, we needed help from a professional designer, and Chloe Minkyoung Lee at Studio PEEK was the one we looked for. She was not only talented, but patient to wait until we were fully satisfied with every single detail. The result was a beautiful logo for CCADD.

The chains left to the text in the logo symbolize links between various disciplines through convergence approaches. They also denote two small letters d, which stand for drug development. Furthermore, if you take out the short bar from the end of each chain, it becomes letter c. So, now we have two c's, and they represent center for convergence. Voila again!

[NEWS]

Dr. Yuchae Jung joined CCADD

Dr. Yuchae Jung has become a new member of CCADD as a BK21 Professor affiliated with the Graduate School of Convergence Science and Technology, Seoul National University. Previously, Dr. Jung was a Research Professor (2016-2017) and a Research Fellow (2013-2016) at the Department of Pharmacology, Sookmyung Women's University (2016-2017). Dr. Jung also had post-doc research experience at Brigham and Women's Hospital (2010-2012) and SUNY at Albany (2008-2010) in the USA.

Dr. Jung has received a research grant from the Ministry of Science, ICT and Future Planning in Korea, entitled “Smart psychology analysis and healing therapy algorithm”. Dr. Jung’s current research interests include development of innovative convergent analysis methods for biomedical data and artificial intelligence-based patient referral system for clinical trials.

Dr. Howard Lee welcomed Dr. Jung, saying “It is just a right time for CCADD to have Dr. Jung on board. With Dr. Jung’s broad experience and skill sets in computational biomedical science, CCADD’s research palette will have more colors to advance its mission.”

[NEWS]

2017 CCADD summer internship has started

Two young future leaders (Left:Se Rin Lee, Right:Hyewon Hwang) will spend the next eight weeks (July-August, 2017) at CCADD through the summer internship program at the Graduate School of Convergence Science and Technology, Seoul National University. Se Rin goes to Seoul National University College of Engineering in association with the Department of Industrial Engineering. Hyewon Hwang is a fourth-year undergraduate student at the College of Liberal Studies, Seoul National University with a double major in statistics and anthropology.

Se Rin is well-versed in computer programming including Java and Python. She is interested in pursuing a career in the pharmaceutical industry, which has prompted her to take a previous internship at Pfizer Korea, where she explored the possibility of big data mining to increase the success probability of clinical trials. On the other hand, Hyewon wants to study the utility of statistics in guiding decision makings in drug development. She also has an excellent command of English.

[NEWS]

Dr. Howard Lee at the 37th KCR Annual Scientific Meeting

There are several points to consider when granting extrapolation for biosimilars across different indications, for which the biosimilar was not tested in humans. Dr. Howard Lee, one of the pioneers in the regulatory issues pertaining to biosimilar as exemplified in his well-received paper, was invited to speak at the 37th Annual Scientific Meeting of the Korean College of Rheumatology, where he challenged extrapolation of the safety and efficacy data in one indication to another for biosimilars unless backed up by strong scientific justification. Dr. Lee concluded that the regulatory agencies need to exercise caution before granting extrapolated indications to biosimilars. Watch the full presentation below.

[NEWS]

AI to patient eligibility assessment for clinical trials

Dr. Howard Lee spoke at the Regulatory Symposium on May 15, 2017, sponsored by the Korea National Enterprise for Clinical Trials, where he emphasized the potential utility of artificial intelligence and machine learning to streamline clinical trial processes. Particularly, Dr. Lee focused on the current practice of laborious and lengthy eyeballing assessment of patient eligibility, which is inefficient and prone to human errors. Machine learning algorithms using patient’s electronic medical records and clinical trial vectors, strengthened by natural language processing and supervised term expansion, can change the way that clinical research coordinators and physicians screen in potentially eligible patients into the clinical trial. The result is reduction in labor and increase in accuracy. CCADD is looking for collaboration partners in this emerging research field.

[NEWS]

The evolution of the regulatory agency

The regulatory agency should evolve into a science agency, followed by a public health agency and, finally, a visionary leadership agency according to Dr. Howard Lee at the 35th Annual Meeting of the Korean Medical Association on June 30, 2017. Dr. Lee emphasized the importance of self-identity by the regulatory agency, which has to balance between the two seemingly contradicting roles: protecting the public from hazards while advancing the public health by introducing innovative new medicines. He also warned the risk to rely exclusively on a specific discipline such as statistics when making an important regulatory decision in drug approval without paying balanced attention to other competing disciplines including mechanistic exploratory modeling analysis. Dr. Lee’s presentation slide deck can be downloaded here.

[NEWS]

How to design safe, scientific, efficient, and practical early phase clinical trials

Dr. Howard Lee spoke at the Advanced Course for the MFDS Reviewers, sponsored by the Korea Human Resource Development Institute for Health and Welfare on April 27, 2017. This educational activity was to refresh the clinical and nonclinical reviewers at MFDS by giving them a chance to get introduced to new ideas and technologies in drug development, particularly for clinical trial design issues. Dr. Lee provided a thorough review in the design of early clinical drug development trials.

[NEWS]

CCADD website is now official!

The first official website of CCADD is successfully launched today! Please go to http://ccadd.snu.ac.kr/ and look around to find more interesting information.

After months of hard work, dedication, and trial and errors, the CCADD official website has taken its form, which consists of separate tabs of About, People, Research, Publications, Teaching, and Board, the last of which has three sub-tabs: News, Announcements, and Blog.

Congratulations to all! You’ve done a great job!

[PUBLICATIONS]

Lee H, Chung H, Lee S, Lee H, Yang SM, Yoon SH, Cho JY, Jang IJ, Yu KS. LBEC0101, A Proposed Etanercept Biosimilar: Pharmacokinetics, Immunogenicity, and Tolerability Profiles Compared with a Reference Biologic Product in Healthy Male Subjects. BioDrugs. 2017 May 27. doi: 10.1007/s40259-017-0230-9. [Epub ahead of print]

[PUBLICATIONS]

Yi S, Lee H, Jang SB, Byun HM, Yoon SH, Cho JY, Jang IJ, Yu KS. A novel K+ competitive acid blocker, YH4808, sustains inhibition of gastric acid secretion with a faster onset than esomeprazole: randomised clinical study in healthy volunteers. Aliment Pharmacol Ther. 2017 May 21. doi: 10.1111/apt.14148. [Epub ahead of print]

[PUBLICATIONS]

Oh J, Lee S, Lee H, Cho J-Y, Yoon SH, et al. The novel carboxylesterase 1 variant c.662A>G may decrease the bioactivation of oseltamivir in humans. PLoS one. 2017;12(4):e0176320.

CCADD

Center for Convergence Approaches in Drug Development, Graduate School of Convergence Science and Technology, Seoul National University

Room C-208, 145 Gwanggyo-ro, Yeongtong-gu, Suwon-si, Gyeonggi-do, 16229, SOUTH KOREA (Gwanggyo)
Room 406, Building 17, Seoul National University College of Medicine, 103 Daehak-ro, Jongno-gu, Seoul, SOUTH KOREA (Yeon-gun)

Tel: +82-31-888-9189 (Gwanggyo); +82-2-3668-7381 (Yeon-gun)

Fax: +82-31-888-9575

Email: ccadd.snu@gmail.com

ABOUT PRINCIPAL INVESTIGATOR PEOPLE RESEARCH PUBLICATIONS NEWS

SEARCH

CCADD

Center for Convergence Approaches in Drug Development, Graduate School of Convergence Science and Technology, Seoul National University

Room C-208, 145 Gwanggyo-ro, Yeongtong-gu, Suwon-si, Gyeonggi-do, 16229, SOUTH KOREA (Gwanggyo)Room 406, Building 17, Seoul National University College of Medicine, 103 Daehak-ro, Jongno-gu, Seoul, SOUTH KOREA (Yeon-gun)

Room C-208, 145 Gwanggyo-ro, Yeongtong-gu, Suwon-si, Gyeonggi-do, 16229, SOUTH KOREA (Gwanggyo)
Room 406, Building 17, Seoul National University College of Medicine, 103 Daehak-ro, Jongno-gu, Seoul, SOUTH KOREA (Yeon-gun)